Contineum CSO sells 4,170 shares in planned trade
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain reported an open-market sale of 4,170 shares of Class A Common Stock at a weighted average price of $13.1564 per share.
Rhea-AI Filing Summary
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain reported an open-market sale of 4,170 shares of Class A Common Stock at a weighted average price of $13.1564 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on September 23, 2025.
After this transaction, he holds 139,372 shares directly and 10,110 shares indirectly through his spouse. His holdings include 3,268 shares purchased through Contineum’s Employee Stock Purchase Plan on May 15, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 4,170 shares
Net Sell
2 txns
Insider
Lorrain Daniel S.
Role
Chief Scientific Officer
Sold
4,170 shs ($55K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock | 4,170 | $13.1564 | $55K |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Class A Common Stock — 139,372 shares (Direct);
Class A Common Stock — 10,110 shares (Indirect, By Spouse)
Footnotes (3)
- F1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.995 to $13.360, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F3. Includes 3,268 shares purchased through Issuer's Employee Stock Purchase Plan on May 15, 2026.
Key Figures
Shares sold: 4,170 shares
Weighted average sale price: $13.1564 per share
Sale price range: $12.995–$13.360 per share
+4 more
7 metrics
Shares sold
4,170 shares
Open-market sale of Class A Common Stock
Weighted average sale price
$13.1564 per share
Average price for the 4,170 shares sold
Sale price range
$12.995–$13.360 per share
Price range for individual trade executions
Direct holdings after transaction
139,372 shares
Direct Class A Common Stock owned after sale
Indirect holdings by spouse
10,110 shares
Indirect ownership through spouse after transaction
ESPP shares included
3,268 shares
Purchased via Employee Stock Purchase Plan on May 15, 2026
10b5-1 plan adoption date
September 23, 2025
Date trading plan governing the sale was adopted
Key Terms
Rule 10b5-1 trading plan, weighted average price, Employee Stock Purchase Plan, open-market sale
4 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Stock Purchase Plan financial
"Includes 3,268 shares purchased through Issuer's Employee Stock Purchase Plan on May 15, 2026."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Contineum Therapeutics (CTNM) report for Daniel S. Lorrain?
Contineum Therapeutics reported that Chief Scientific Officer Daniel S. Lorrain sold 4,170 shares of Class A Common Stock in an open-market transaction at a weighted average price of $13.1564 per share, according to a Form 4 insider trading report.
Was the CTNM insider sale by Daniel S. Lorrain made under a trading plan?
Yes. The reported sale of 4,170 Contineum Therapeutics shares by Daniel S. Lorrain was executed under a Rule 10b5-1 trading plan adopted on September 23, 2025, indicating the transactions were pre-arranged rather than timed discretionarily.
AI-generated analysis. How Rhea-AI works. Not financial advice.
